Hormonal contraception and the skin

European Journal of Contraception and Reproductive Health Care

Volumn 3, Issue 1, 1998, Pages 17-19

  Giannotti, B ^a   Carli, P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acne; Antiandrogens; Oral contraceptives; Skin

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ACNE VULGARIS; CHEMISTRY; CONGENITAL MALFORMATION; DRUG EFFECT; FEMALE; FETUS; HUMAN; PATHOLOGY; PREGNANCY; REVIEW;

ABNORMALITIES, DRUG-INDUCED; ACNE VULGARIS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; FETUS; HUMANS; PREGNANCY;

EID: 0032012107     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189809167480     Document Type: Article

References (6)

1. Leyden JJ. Therapy for acne vulgaris. N Engl J Med 1997; 33: 1156-61
2. Erkkola R, Hirvonen E, Luikku J, Lumme R, Manikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 1990; 69: 61-5
3. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud 1996; 41: 423-9
4. Redmond GP, Olson WH, Lipman JS, Kafrissen ME, Jones TM,Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized,placebo-controlled trial. Obstet Gynecol 1997; 41: 615-22
5. Rosa FW. Teratogenicity of isotretinoin. Lancet 1983; 2:513
6. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-6